Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease
Ambulero Inc Receives Key FDA Recognition For Novel Gene Therapy To Treat Buerger’s Disease (Thromboangiitis Obliterans) MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) — Ambulero Inc.,